about
Rapid Switch From Flolan to Remodulin in the Outpatient ClinicStudy of Intravenous Remodulin in Patients in India With Pulmonary Arterial HypertensionSafety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial HypertensionSorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease ManagementCardiac Magnetic Resonance Imaging and Pulmonary PerfusionHemodynamic Changes in Connective Tissue DiseaseStudy of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial HypertensionApabetalone for Pulmonary Arterial Hypertension: a Pilot StudyInhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary FibrosisGoal Oriented Strategy to Preserve Ejection Fraction TrialThe PAH Disability and Bothersomeness QuestionnairePulmonary Hypertension and Anastrozole TrialThe Assessment of Right Ventricular Contractility in Response to SildenafilSafety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) SubjectsA Mobile Health Intervention in Pulmonary Arterial HypertensionExtended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGERDrug Therapy and Surgery in Congenital Heart Disease With Pulmonary HypertensionImpact of Inhaled Treprostinil Sodium on Ventilation Perfusion MatchingPeripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial HypertensionPilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial HypertensionFUTURE 3 Study ExtensionEfficacy of Ventavis Used in Real-life Setting.Safely Change From Bosentan to Ambrisentan in Pulmonary HypertensionPRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension4DFlow Magnetic Resonance Imaging in Patients With Pulmonary Hypertension Associated With Congenital Heart DiseaseStudy to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial HypertensionNon-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic SclerosisHemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of TreprostinilOlaparib for PAH: a Multicenter Clinical TrialThis Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and ChronicObservation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial HypertensionPositioning Imatinib for Pulmonary Arterial Hypertension
P921
Q61914607-D352BD10-F2FC-4C36-AF80-021AFAB1D287Q61917681-E92DCEBC-E2AB-46F1-BD07-66597A28E67FQ61920799-C88D9CCD-26F1-48C2-B9E1-544F157D5DCBQ61920893-193C8C8A-3E5B-4FF2-AAF1-B545858A04F3Q61933378-C83B25A3-AC0F-453E-9D8C-AD614AF5118FQ61936151-5465BDE1-E056-4CC6-B884-446AC4D31510Q61955923-25797894-1327-42D2-A6A5-7FAC6A83624EQ61957057-1DDF88CF-7C2A-4294-8B80-74DC4EE6ECC6Q61965933-E668C7FB-65E3-48DA-B8FA-49BD141C40C2Q61975684-F96138BD-D953-4775-B98B-85566C529DF7Q61981224-65EB8C6D-27C1-4724-ADDB-E10E62CED02CQ62024954-A5659845-E052-4E03-8827-58E22CB7FBF0Q62105338-EA8731A9-8FC0-43CE-92F8-4C92D338258AQ63011144-DDC29A0C-C34C-4CCC-83BE-166BC00B5FECQ63011491-33C4C0BD-A6D7-4C58-BDF5-B158D4D667DBQ63012872-1C7CFC85-294B-4BA5-8955-6193286477E2Q63062632-D33D7BF4-04C0-4C51-8FDE-F9CD42EF14B3Q63062656-8FDC2F0D-F427-4951-BB44-58AEF26F4038Q63229156-55682CF1-C184-4001-8C04-ED71CA54A8ACQ63229303-57737C28-7388-4283-A276-0818BDDB0244Q63316272-2F14F45F-BF78-4F62-ABB3-0581E30B7014Q63319577-FD2E63CD-D1E2-405B-9E22-BCD8FF466B1AQ63320380-11532C81-D3FA-421E-8AC4-8D44872610C3Q63321621-DD43FFB2-8D69-4792-8253-B5F785DFAB7AQ63333804-D1058697-3614-40D3-88BD-72D0FDA0169EQ63335406-6A2E0CD6-1376-4CC6-9BFE-A024916B7AAAQ63337194-D37A5BAA-FF41-4E7F-B78A-D91AC1476738Q63338078-8B38530E-B610-4735-9733-E267095273E3Q63400966-1DA86FD0-D331-4954-9B8B-5029C6620D9BQ63405574-F884AFAE-2A3E-458B-9F20-1C5A8E585C40Q63572177-888A6A70-5CBC-4DDB-9647-B62EEA8BE96DQ63572745-9107C723-ED93-4556-BB3E-33274B97414FQ63577697-089A5F71-DE02-4E10-AFB3-7B43E6D5078EQ63580931-06C5A85A-B935-4520-8B69-2D4B0E848DE5Q63582161-10C74281-DBF4-47DF-96A1-AFA24B18CB11Q63593103-F816EA1F-8567-4409-9C20-26BC8B95D4CFQ63811622-1C00FD6B-4056-498E-A5FE-8412B56D946AQ87932050-3CA8A3E7-19AE-40FE-B461-B54877FA11A7Q96143592-1C4C7AD2-45FC-46BB-A5CD-8FEE2CF7A5B7
P921
description
human disease
@en
name
pulmonary hypertension, primary, 1
@en
type
label
pulmonary hypertension, primary, 1
@en
altLabel
PPH1
@en
PULMONARY HYPERTENSION, PRIMARY, 1; PPH1
@en
Pht
@en
Pph1 With Hht
@en
Pulmonary Arterial Hypertension
@en
Pulmonary Hypertension, Primary, 1, With Hereditary Hemorrhagic Telangiectasia
@en
Pulmonary Hypertension, Primary, Dexfenfluramine-Associated
@en
Pulmonary Hypertension, Primary, Fenfluramine-Associated
@en
prefLabel
pulmonary hypertension, primary, 1
@en
P2892
P2888
P2892
P492
P5270
MONDO:0024533